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Previous trials suggesting that high-frequency oscillatory
ventilation (HFOV) reduced mortality among adults
with the acute respiratory distress syndrome (ARDS)
were limited by the use of outdated comparator ventila-
tion strategies and small sample sizes.Methods
Objective: The aim of the study was to compare HFOV
with a conventional ventilation strategy that used low
tidal volumes and high levels of positive end-expiratory
pressure in patients with new-onset, early (<72 hours)
moderate to severe ARDS.
Design: A multicenter, randomized, controlled trial
was conducted in 39 ICUs in five countries.
Setting: Participants were adults with new-onset, mod-
erate to severe ARDS.
Intervention: Patients were randomly assigned to
HFOV targeting lung recruitment or to a control venti-
lation strategy targeting lung recruitment with the use of
low tidal volumes and high positive end-expiratory
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2014Measurements: The primary outcome was the 60-day
in-hospital mortality from any cause. Secondary out-
comes included ICU mortality, 28-day mortality, new
barotrauma, new tracheostomy, refractory hypoxemia,
refractory acidosis, mechanical ventilation duration in
survivors, ICU duration in survivors, and hospitalization
in survivors.
Results
On the recommendation of the data monitoring commit-
tee, we stopped the trial after 548 out of a planned 1,200
patients had undergone randomization. The two study
groups were well matched at baseline. The HFOV group
underwent HFOV for a median of 3 days (interquartile
range, 2 to 8); in addition, 34 of 273 patients (12%) in the
control group received HFOV for refractory hypoxemia.
In-hospital mortality was 47% in the HFOV group, as
compared with 35% in the control group (relative risk of
death with HFOV, 1.33; 95% confidence interval, 1.09 to
1.64; P = 0.005). This finding was independent of baseline
abnormalities in oxygenation or respiratory compliance.
Patients in the HFOV group received higher doses of mid-
azolam than did patients in the control group (199 mg/
day (interquartile range, 100 to 382) vs. 141 mg/day (inter-
quartile range, 68 to 240), P < 0.001), and more patients in
the HFOV group than in the control group received
neuromuscular blockers (83% vs. 68%, P < 0.001). In
addition, more patients in the HFOV group received vaso-
active drugs (91% vs. 84%, P = 0.01) and received them for
a longer period than did patients in the control group
(5 days vs. 3 days, P = 0.01).
Conclusions
In adults with moderate-to-severe ARDS, early application
of HFOV, as compared with a ventilation strategy of low
tidal volume and high positive end-expiratory pressure,
does not reduce, and may increase, in-hospital mortality.tral Ltd. This is an Open Access article distributed under the terms of the
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respiratory distress syndrome (ARDS) management. Low
tidal volume (6 ml/kg) ventilation has been shown to
reduce mortality [1], raising the question of whether
high-frequency oscillatory ventilation (HFOV) with even
lower tidal volumes will be even more beneficial. The
theory behind HFOV is to couple a very small tidal
volume (approximately 1 to 2 ml/kg) with a very high
respiratory rate (3 to 15 breaths/second), thus providing a
constant mean airway pressure, and limiting alveolar over-
distension and repetitive collapse and reopening injury.
In the United States, HFOV has been sporadically used
in adult ARDS patients after the US Food and Drug Ad-
ministration cleared it for pediatric use in the 1990s. A
2010 meta-analysis of HFOV versus conventional venti-
lation (CV) for ARDS pooled six trials. The meta-
analysis included four adult trials, a total of 291 adult
patients. The study concluded that HFOV might reduce
hospital mortality in patients with ARDS compared with
CV and is unlikely to cause harm [2]. However, some of
the trials did not use lung-protective ventilation in the
CV group [2-4].
HFOV has been used in ARDS patients as a rescue
therapy. More recently, HFOV has been used as primary
or secondary therapy early in the disease course, with
some evidence of success [5,6]. However, the efficacy of
HFOV in adults with early ARDS has not been proven.
The current OSCILLATE trial sought to address this
clinical question.
The OSCILLATE trial compared HFOV with a CV
strategy that used low tidal volumes and high levels of
positive end-expiratory pressure in patients with new-
onset, early (<72 hours since onset of respiratory failure),
moderate to severe ARDS. The primary outcome was
hospital mortality. Patients discharged from hospital
were assumed to be alive at 60 days. Secondary out-
comes were mortality at other time points, barotrauma,
organ dysfunction, duration of ventilation, and duration
of ICU and hospital stay. The study cohort was relatively
young (mean age 55 years) and had high acuity (mean
Acute Physiology and Chronic Health Evaluation II score
of 29). Approximately one-half of the patients had sepsis
and/or pneumonia. Close to two-thirds were on vaso-
pressors or inotropes at baseline. In-hospital mortality
was 47 % in the HFOV group, as compared with 35 % in
the control group (P = 0.005).
The OSCILLATE trial was a well-conducted, large,
multicenter trial performed in several countries. The
HFOV protocol was standardized based on pilot testing
and consensus guidelines. There was concern for a
learning curve associated with the use of HFOV, and
most patients were enrolled at centers that were experi-
enced with HFOV. However, subgroup analyses did not
detect an interaction between treatment effect and thenumber of patients enrolled per site. Why then did the
OSCILLATE trial demonstrate harm with HFOV?
First, the HFOV group received more sedatives and
vasoactive drugs (91% vs. 84%, P = 0.01). Vasoactive
drugs and neuromuscular blockers were administered
for longer in the HFOV group. One mechanism for
hypotension in HFOV is that high intrathoracic pres-
sures lead to decreased preload and right ventricular
dysfunction, and consequently hemodynamic comprom-
ise. Sedatives and opioids (most commonly midazolam
and fentanyl) that can cause vasodilatation were admin-
istered for the same duration in the two groups (median
10 days), but during the first week the median doses
were higher in the HFOV group.
Second, central venous pressure was used for volume
assessment. The study used central venous pressure
greater than 12 cmH2O as the cutoff point for adequate
intravascular volume prior to initiating the study proto-
col. Central venous pressure is an imperfect surrogate
for volume status and preload. Central venous pressure
less than 12 cmH2O does not necessarily indicate inad-
equate volume status. Echocardiogram, pulse pressure
variation, or other monitoring technologies could be
used for more accurate intravascular volume monitoring
during HFOV.
Third, the OSCILLATE trial used recruitment maneu-
vers and relatively high mean airway pressure; initial
mean airway pressures were 30 cmH2O and often in-
creased up to 38 cmH2O. The OSCAR trial did not use
mandatory recruitment maneuvers and set the initial
mean airway pressure to 5 cmH2O above the peak plat-
eau pressure (mean mean airway pressure 26.9 cmH2O
on day 1 and 25.1 cmH2O on day 3) and showed no
harm with HFOV compared with CV [7]. In contrast to
results of the OSCILLATE trial, there was no difference
in 30-day mortality and no significant difference in the
duration of inotropic agents or pressor use between
HFOV and CV in the OSCAR trial.
The OSCILLATE trial found that HFOV did not re-
duce, and may increase, mortality in early ARDS pa-
tients. Further study of the ideal HFOV setting and
appropriate patient population and hemodynamic moni-
toring during HFOV are warranted.
Recommendation
Based on the results of this large multicenter random-
ized trial, HFOV is not recommended over CV with low
tidal volume in early ARDS.
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